KPV 10mg

KPV is a synthetic tripeptide composed of the amino acids lysine-proline-valine (Lys-Pro-Val). It corresponds to the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH), residues 11–13 of the parent 13-amino-acid hormone. Despite its small size — only three amino acids — KPV has been the subject of substantial research focused on its anti-inflammatory effects, particularly in gastrointestinal and dermatological contexts. The fragment retains some of the anti-inflammatory and immune-modulating properties of the parent α-MSH while lacking the pigmentation effects associated with full-length α-MSH activation of melanocortin receptors.

It is sold for laboratory and analytical research only and is not approved by the U.S. Food and Drug Administration for any therapeutic indication.

Molecular Structure and Stability

KPV is a tripeptide with the sequence Lys-Pro-Val, molecular formula C₁₆H₃₀N₄O₄, and molecular weight of approximately 342.4 Daltons. The three-amino-acid structure makes it one of the smallest peptides in research applications — small enough to potentially access cellular targets that larger peptides cannot reach. The compound was identified through systematic research into the bioactive fragments of α-MSH, where investigators examined which portions of the parent hormone retained which biological activities.

The lyophilized (freeze-dried) form supplied for research is stable at -20°C for up to 24 months when sealed and protected from moisture. Following reconstitution with bacteriostatic water, the compound retains research-grade integrity for approximately 30 days when refrigerated at 2–8°C and protected from light. Repeated freeze-thaw cycles should be avoided.

Mechanism of Action — Pathways Active in Human Inflammatory Biology

KPV's research portfolio centers on anti-inflammatory and immune-modulating mechanisms. The pathways studied are central to multiple chronic inflammatory conditions in human medicine.

NF-κB pathway suppression. Nuclear factor kappa-B (NF-κB) is a master transcription factor regulating inflammatory gene expression in human cells. Research has documented KPV-associated suppression of NF-κB activation in response to inflammatory stimuli, with downstream effects on inflammatory cytokine production. NF-κB inhibition is the mechanism behind multiple anti-inflammatory therapeutics in human medicine including some glucocorticoids and biologics.

Pro-inflammatory cytokine modulation. Research has documented KPV-associated reductions in the production of pro-inflammatory cytokines including interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-α), and others. These cytokines are central to chronic inflammatory conditions in human medicine and are targeted by major biologic therapies including anti-TNF drugs (Humira, Remicade) and anti-IL-6 drugs (tocilizumab) used in rheumatoid arthritis, inflammatory bowel disease, and other autoimmune conditions.

Mast cell stabilization. Research has examined KPV effects on mast cell biology, with documented effects on mast cell degranulation and histamine release. Mast cells are central to allergic and inflammatory responses in human tissues, including in skin, gastrointestinal tract, and respiratory system.

Wound healing and dermal biology. Research has examined KPV effects on dermal healing, including effects in human keratinocyte cultures and animal models of skin inflammation. The combination of anti-inflammatory and tissue repair effects has driven research interest in dermatological applications.

Gastrointestinal inflammation. One of the most extensively researched application areas for KPV is inflammatory bowel disease. Research has documented effects in animal models of ulcerative colitis (DSS-induced colitis) and Crohn's disease analogues, with documented reductions in inflammatory markers, improved mucosal healing, and reduced disease activity scores. The PepT1 transporter — expressed on intestinal epithelial cells — has been implicated as one mechanism by which KPV may directly access intestinal cells.

PepT1 transporter and direct epithelial uptake. KPV is a substrate for the peptide transporter PepT1, which is expressed on intestinal epithelial cells (and upregulated during inflammation in IBD contexts). This allows direct cellular uptake of KPV by inflamed intestinal epithelium, providing a mechanistic basis for the gastrointestinal anti-inflammatory effects observed in research.

Melanocortin receptor independence. Notably, KPV does not significantly activate melanocortin receptors (MC1R-MC5R) — distinguishing it pharmacologically from the parent α-MSH peptide. This means KPV does not produce the pigmentation effects associated with α-MSH activation of MC1R, while retaining anti-inflammatory effects through MC-receptor-independent mechanisms.

Human Research and Clinical Context

KPV has a research portfolio spanning preclinical animal models, in vitro studies in human cell cultures, and limited human clinical research.

Inflammatory bowel disease research. The most extensively researched human-relevant application area for KPV is inflammatory bowel disease. Research from groups including Didier Merlin's at Emory University has documented KPV effects in IBD-relevant models, including direct epithelial uptake through PepT1 and reduced inflammation in established colitis. IBD affects approximately 3 million Americans with significant unmet need for therapeutic options beyond existing biologics and small molecules.

Dermatological research. Research has examined KPV in human skin contexts including atopic dermatitis, psoriasis, and contact dermatitis models. The combination of anti-inflammatory effects without melanocortin receptor activation makes the compound interesting for dermatological research where pigmentation effects would be undesirable.

Allergic inflammation research. Research has examined KPV in the context of allergic responses including effects on mast cell function and histamine-mediated inflammation, with relevance to allergic skin conditions and potentially asthma research.

Translational research areas with substantial human clinical relevance:

• Inflammatory bowel disease — affecting approximately 3 million Americans with substantial morbidity and need for novel therapeutic approaches beyond existing biologics
• Atopic dermatitis and psoriasis — affecting tens of millions of Americans with significant impact on quality of life
• Allergic and mast cell-mediated conditions — relevant to a wide range of human inflammatory conditions
• Wound healing in inflammatory contexts — relevant to chronic wounds, post-surgical recovery, and dermatological repair
• α-MSH fragment biology — KPV represents one of the most studied α-MSH fragments and informs broader research into how the various biological activities of melanocortin hormones can be separated and individually targeted

The translation of preclinical findings to clinical applications remains an active area of investigation. Researchers should consult primary literature for the most current human clinical research status.

Quality Verification — What Our COA Documents

Every batch of KPV supplied by Elara is independently analyzed by a third-party laboratory before release. Our Certificate of Analysis documents two distinct verification measures:

HPLC purity (≥99%). High-performance liquid chromatography separates the synthesized tripeptide from synthesis-related impurities, truncation sequences, and degradation products. Our specification requires a minimum 99% purity at the main peak. For a small tripeptide, achieving high purity is more straightforward than for larger peptides, but verification is still important to confirm the correct KPV sequence is supplied.

Mass spectrometry identity confirmation. MS analysis confirms that the molecular weight of the peak compound matches the theoretical molecular weight of KPV (~342.4 Da), verifying both structural identity and the correct Lys-Pro-Val sequence.

The COA accompanies every shipment and is also available for download on this product page.

Reconstitution and Handling for Research

For laboratory research applications, KPV is typically reconstituted using bacteriostatic water (0.9% benzyl alcohol). Standard practice involves slow addition of solvent along the inside wall of the vial — never directly onto the lyophilized powder, which can cause aggregation. The vial is then gently swirled (not shaken or vortexed) until the peptide is fully dissolved.

Once reconstituted, the solution should be stored at 2–8°C, protected from light, and used within 30 days for optimal molecular integrity. Sterile technique is essential during all handling steps. Researchers performing in vitro work or animal model studies should refer to their institution's IACUC protocols and standard handling guidelines specific to their experimental design.

Frequently Asked Questions

What is KPV?
KPV is a synthetic tripeptide composed of lysine-proline-valine, corresponding to the C-terminal three amino acids of alpha-melanocyte-stimulating hormone (α-MSH residues 11–13). It has been studied for anti-inflammatory effects in gastrointestinal, dermatological, and broader inflammatory contexts, and is one of the smallest peptides in research applications.

How is KPV different from α-MSH?
α-MSH is a 13-amino-acid hormone with multiple biological activities including pigmentation effects (through MC1R activation), anti-inflammatory effects, appetite regulation (through MC4R), and others. KPV represents only the C-terminal three amino acids, which research has shown retain the anti-inflammatory effects while lacking significant melanocortin receptor activation. This means KPV produces anti-inflammatory effects without the pigmentation effects characteristic of full-length α-MSH.

How does such a small peptide produce biological effects?
KPV operates through several mechanisms that don't require classical receptor binding. Direct cellular uptake through the PepT1 peptide transporter (particularly relevant in inflamed intestinal epithelium), intracellular effects on NF-κB signaling, and mast cell stabilization are among the documented mechanisms. The small size that might seem like a pharmacological limitation actually enables certain mechanisms — including direct intracellular access through PepT1 — that larger peptides cannot achieve.

Has KPV been studied in humans?
KPV has been studied in human cell cultures (including human intestinal epithelial cells, keratinocytes, and immune cells) and in animal models relevant to human inflammatory conditions. Direct human clinical trial data is more limited than for some other research peptides. Researchers should consult primary literature for the most current human clinical research status.

What is PepT1 and why is it relevant?
PepT1 is a peptide transporter expressed on intestinal epithelial cells that normally transports dietary di- and tripeptides for absorption. PepT1 expression is upregulated in inflammatory bowel disease, and KPV is a substrate for this transporter — meaning KPV can be directly absorbed by inflamed intestinal epithelium where it then exerts anti-inflammatory effects intracellularly. This mechanism makes the gastrointestinal anti-inflammatory research particularly compelling for IBD applications.

What does HPLC ≥99% purity actually mean?
High-performance liquid chromatography is the analytical standard for assessing peptide purity. A specification of ≥99% indicates that, of all UV-detectable species in the analyzed sample, at least 99% of the integrated peak area corresponds to the target compound. For KPV, the simple tripeptide structure makes high purity achievable but verification still important to confirm the correct sequence.

How long is KPV stable after reconstitution?
Reconstituted KPV retains research-grade integrity for approximately 30 days when stored refrigerated at 2–8°C and protected from light. Avoid freeze-thaw cycles. Lyophilized (unreconstituted) KPV is stable at -20°C for up to 24 months when properly sealed.

What human pathways does KPV research target?
The most-studied pathways with direct human clinical relevance include NF-κB signaling (master transcription factor for inflammatory gene expression), pro-inflammatory cytokine production (IL-6, IL-8, TNF-α — the same pathways targeted by major biologic medications), mast cell stabilization, intestinal epithelial inflammation through PepT1-mediated uptake, and dermal inflammation in skin biology research.

Does Elara test every batch?
Yes. Every production batch of KPV receives independent third-party HPLC and mass spectrometry analysis before release. Batches that do not meet our 99% purity specification are rejected. The COA documenting analytical results for the specific batch you receive is included with every shipment and available for download above.